Business Overview
The Kyorin Group will continue its concerted efforts to discover and develop new drugs. While doing so, it will build the same relationships of trust with patients, their families and other consumers as it has with medical workers.
The Group comprises KYORIN Pharmaceutical Co., Ltd., KYORIN Rimedio Co., Ltd., Dr. Program Co., Ltd., and Kyobundo Co., Ltd. These companies focus on the core drug discovery and pharmaceuticals business: the generic drugs business, which provides reliable products; and the consumer healthcare business, which is supported by physician recommendations. The Group will channel management resources into these areas and promote more-eficient business activities.
Ethical Drug
We engage in the drug discovery business, ethical drug sales in Japan and ethical drug sales overseas.
Trends in major new products are also posted. Click here for details about Products under Development for details.
Generic Drug Business
Generic Drug Business that Provides Reliable Products.
Consumer Healthcare Business
Consumer Healthcare Business that is supported by Physician Recommendations.
Other Businesses
Kyobundo Co., Ltd.
